Importance of genetic screens in precision oncology

被引：8
作者：
Mulero-Sanchez, Antonio [1 ]
Pogacar, Ziva [1 ]
Vecchione, Loredana [2 ]
机构：
[1] Netherlands Canc Inst, Oncode Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands
[2] Charite Univ Med Berlin, Charite Comprehens Canc Ctr, Berlin, Germany
来源：
ESMO OPEN | 2019年 / 4卷 / 03期
关键词：
METASTATIC COLORECTAL-CANCER; SYNTHETIC LETHALITY; TRASTUZUMAB RESISTANCE; PIK3CA MUTATIONS; MEK INHIBITION; PHASE IB; BRAF; CELLS; VEMURAFENIB; ACTIVATION;
D O I：
10.1136/esmoopen-2019-000505
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Precision oncology aims to distinguish which patients are eligible for a specific treatment in order to achieve the best possible outcome. In the last few years, genetic screens have shown their potential to find the new targets and drug combinations as well as predictive biomarkers for response and/or resistance to cancer treatment. In this review, we outline how precision oncology is changing over time and describe the different applications of genetic screens. Finally, we present some practical examples that describe the utility and the limitations of genetic screens in precision oncology.
引用
收藏
页数：10
相关论文
共 96 条
  • [1] A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response
    Adamson, Britt
    Norman, Thomas M.
    Jost, Marco
    Cho, Min Y.
    Nunez, James K.
    Chen, Yuwen
    Villalta, Jacqueline E.
    Gilbert, Luke A.
    Horlbeck, Max A.
    Hein, Marco Y.
    Pak, Ryan A.
    Gray, Andrew N.
    Gross, Carol A.
    Dixit, Atray
    Parnas, Oren
    Regev, Aviv
    Weissman, Jonathan S.
    [J]. CELL, 2016, 167 (07) : 1867 - +
  • [2] [Anonymous], Venetoclax Plus Dexamethasone Shows Activity in Multiple Myeloma
  • [3] [Anonymous], CANC GEN ATL
  • [4] ASCO, TARG AG PROF UT REG
  • [5] E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer
    Bajrami, Ilirjana
    Marlow, Rebecca
    van de Ven, Marieke
    Brough, Rachel
    Pemberton, Helen N.
    Frankum, Jessica
    Song, Feifei
    Rafiq, Rumana
    Konde, Asha
    Krastev, Dragomir B.
    Menon, Malini
    Campbell, James
    Gulati, Aditi
    Kumar, Rahul
    Pettitt, Stephen J.
    Gurden, Mark D.
    Cardenosa, Marta Llorca
    Chong, Irene
    Gazinska, Patrycja
    Wallberg, Fredrik
    Sawyer, Elinor J.
    Martin, Lesley-Ann
    Dawsett, Mitch
    Linardopoulos, Spiros
    Natrajan, Rachael
    Ryan, Calm J.
    Derksen, Patrick W. B.
    Jonkers, Jos
    Tutt, Andrew N. J.
    Ashworth, Alan
    Lord, Christopher J.
    [J]. CANCER DISCOVERY, 2018, 8 (04) : 498 - 515
  • [6] Bang YJ, 2010, LANCET, V376, P1302
  • [7] Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer
    Baselga, Jose
    Perez, Edith A.
    Pienkowski, Tadeusz
    Bell, Richard
    [J]. ONCOLOGIST, 2006, 11 : 4 - 12
  • [8] Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer
    Baselga, Jose
    Phillips, Gail D. Lewis
    Verma, Sunil
    Ro, Jungsil
    Huober, Jens
    Guardino, Alice E.
    Samant, Meghna K.
    Olsen, Steve
    de Haas, Sanne L.
    Pegram, Mark D.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3755 - 3763
  • [9] A large-scale RNAi screen in human cells identifies new components of the p53 pathway
    Berns, K
    Hijmans, EM
    Mullenders, J
    Brummelkamp, TR
    Velds, A
    Heimerikx, M
    Kerkhoven, RM
    Madiredjo, M
    Nijkamp, W
    Weigelt, B
    Agami, R
    Ge, W
    Cavet, G
    Linsley, PS
    Beijersbergen, RL
    Bernards, R
    [J]. NATURE, 2004, 428 (6981) : 431 - 437
  • [10] A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
    Berns, Katrien
    Horlings, Hugo M.
    Hennessy, Bryan T.
    Madiredjo, Mandy
    Hijmans, E. Marielle
    Beelen, Karin
    Linn, Sabine C.
    Gonzalez-Angulo, Ana Maria
    Stemke-Hale, Katherine
    Hauptmann, Michael
    Beijersbergen, Roderick L.
    Mills, Gordon B.
    de Vijver, Marc J. van
    Bernards, Rene
    [J]. CANCER CELL, 2007, 12 (04) : 395 - 402
12345678910